Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CBFB | Q13951 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6759961 | 0.83 | BRAF (0.48) | BRAFTGFBR1MTORMETAP2KDM4E | |
| SCHEMBL4101340 | 0.80 | BRAF (0.52) | BRAFMAPK14TGFBR1MTORMAPK13 | |
| SCHEMBL4101328 | 0.79 | TGFBR1 (0.41) | BRAFMAPK14TGFBR1MTORMAPK13 | |
| SCHEMBL6764691 | 0.77 | TGFBR1 (0.48) | BRAFMAPK14TGFBR1MTORMAPK13 | |
| SCHEMBL6222973 | 0.75 | TGFBR1 (0.50) | BRAFMAPK14TGFBR1MTORRIPK2 | |
| SCHEMBL8924110 | 0.73 | ESR1 (0.45) | TGFBR1MTORCBFBMETAP2KDM4E | |
| SCHEMBL28155744 | 0.72 | IDO1 (0.51) | TGFBR1TDP1MAPTCBFBKDM4E | |
| SCHEMBL6228248 | 0.71 | TGFBR1 (0.56) | BRAFMAPK14TGFBR1MTORRIPK2 | |
| SCHEMBL4090666 | 0.71 | TGFBR1 (0.36) | TGFBR1KDM4ENPC1GRM5 | |
| SCHEMBL6757498 | 0.67 | KDM4E (0.49) | TGFBR1TDP1MAPTCBFBMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | INCYTE CORPORATION | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | JAK1, JAK2, JAK3 | BRAF 161/4885MAPK14 136/4885TGFBR1 1257/4885 |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | JAK1, JAK2, JAK3 | BRAF 161/4885MAPK14 136/4885TGFBR1 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.